The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Various cyclin-dependent kinase (Cdk) complexes have been implicated in the regulation of transcription. In this study, we identified a 70-kDa Cyclin K (CycK) that binds Cdk12 and Cdk13 to form two different complexes (CycK/Cdk12 or CycK/Cdk13) in human cells. The CycK/Cdk12 complex regulates phosphorylation of Ser2 in the C-terminal domain of RNA polymerase II and expression of a small subset of human genes, as revealed in expression microarrays. Depletion of CycK/Cdk12 results in decreased expression of predominantly long genes with high numbers of exons. The most prominent group of down-regulated genes are the DNA damage response genes, including the critical regulators of genomic stability: BRCA1 (breast and ovarian cancer type 1 susceptibility protein 1), ATR (ataxia telangiectasia and Rad3-related), FANCI, and FANCD2. We show that CycK/Cdk12, rather than CycK/Cdk13, is necessary for their expression. Nuclear run-on assays and chromatin immunoprecipitations with RNA polymerase II on the BRCA1 and FANCI genes suggest a transcriptional defect in the absence of CycK/Cdk12. Consistent with these findings, cells without CycK/Cdk12 induce spontaneous DNA damage and are sensitive to a variety of DNA damage agents. We conclude that through regulation of expression of DNA damage response genes, CycK/Cdk12 protects cells from genomic instability. The essential role of CycK for organisms in vivo is further supported by the result that genetic inactivation of CycK in mice causes early embryonic lethality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Micro3 showed similarities to HM_3, HM_4 phenotype but also expressed APOE, apoptosis associated genes XAF1, YWHAB, YWHAG, YWHAE encoding 14–3-3 protein subunits, cell-cycle and cell division control genes CDK12, MIS18BP1, TAF1D, BOD1L1 and CCAR1 [6, 30, 67].”
From Characterisation of premature cell senescence in Alzheimer's disease using single nuclear transcriptomics (2024) · cites this paper as [6]
In the citing paper
“To execute their functions, CDK12 and CDK13 form two separate complexes with CCNK (Blazek et al., 2011; Cheng et al., 2012).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Blazek et al., 2011
In the citing paper
“CDK12 inactivation is known to cause reduced POLII elongation and premature polyadenylation of select genes enriched in the DNA damage response pathway, resulting in a BRCAness phenotype (Blazek et al., 2011; Dubbury et al., 2018; Johnson et al., 2016).”
From Discovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation (2020) · cites this paper as Blazek et al., 2011
In the citing paper
“CDK12 forms a complex with CCNK to act as a transcriptional regulator of genes critically involved in DDR pathways (Blazek et al., 2011;Krajewska et al., 2019).”
From Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer (2021) · cites this paper as Blazek et al., 2011
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 4×
“DDR operates through a large network of proteins; however, some proteins lie at the core of DDR mechanisms and regulate responses to several types of lesions (Matsuoka et al. 2007; Jackson and Bartek 2009; Ciccia and Elledge 2010).”
BackgroundInfluentialThe DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368
ATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075 · cited 2×
“DDR operates through a large network of proteins; however, some proteins lie at the core of DDR mechanisms and regulate responses to several types of lesions (Matsuoka et al. 2007; Jackson and Bartek 2009; Ciccia and Elledge 2010).”
BackgroundThe DNA Damage Response: Ten Years After
Harper, J. W., & Elledge, S. J. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.11.015 · Cited by 1,705
Bonner, W. M., Redon, C. E., Dickey, J. S., Nakamura, A. J., Sedelnikova, O. A., Solier, S., & Pommier, Y. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2523 · Cited by 1,623 · cited 2×
“DNA double-stranded breaks (DSBs) and DNA interstrand cross-links (ICLs) are among the most severe DNA lesions (Harper and Elledge 2007; Bonner et al. 2008; Jackson and Bartek 2009; Moldovan and D’Andrea 2009).”
Backgroundc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279 · cited 1×
“P-TEFb is considered to be the major Ser2 kinase and was implicated in the regulation of transcriptional elongation of most, if not all, protein-coding genes (Chao et al. 2000; Nechaev and Adelman 2008; Rahl et al. 2010).”
BackgroundControlling the elongation phase of transcription with P-TEFb
Peterlin, B. M., & Price, D. H. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.06.014 · Cited by 1,144 · cited 3×
“Phosphorylation of serine at position 2 (Ser2) is thought to be responsible for productive transcriptional elongation and synthesis of full-length mature mRNA (Peterlin and Price 2006; Bres et al. 2008).”
BackgroundSelf-citationRecruitment of P-TEFb for Stimulation of Transcriptional Elongation by the Bromodomain Protein Brd4
Yang, Z., Yik, J. H. N., Chen, R., He, N., Jang, M. K., Ozato, K., & Zhou, Q. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.06.029 · Cited by 1,138 · cited 13×
“To determine how depletion of P-TEFb and the CycK/Cdk12 complex affects BRCA1 protein levels and global phosphorylation of Ser2, we knocked down both cyclin subunits of P-TEFb and the CycK/Cdk12 complex (Fig.”
BackgroundInfluentialiCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution
König, J., Zarnack, K., Rot, G., Curk, T., Kayikci, M., Zupan, B., Turner, D. J., Luscombe, N. M., & Ule, J. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1838 · Cited by 1,126 · cited 1×
“CEL files were first analyzed with version 3 of ASPIRE software (Konig et al. 2010).”
MethodSelf-citation
Research works printed but not linked: 1
- 10.1038/nature10166 · DOI · Paper page
Cited by
The Molecular Taxonomy of Primary Prostate Cancer
Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, C. D., Annala, M., Aprikian, A., Armenia, J., Arora, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.025 · Cited by 3,110
“Four tumors (1%) possessed either loss-of-function mutations or homozygous deletion of CDK12, a gene that has been implicated in DNA repair by regulating expression levels of several DNA damage response genes (Blazek et al., 2011) and is recurrently mutated in metastatic prostate cancer (Grasso et al.”
BackgroundMalumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
“Recent studies in Drosophila and human cells suggest that Cdk12, in complex with cyclin K, is the yeast Ctk1 ortholog responsible for most of the Ser2 phosphorylation at the CTD and especially the phosphorylation at promoter-distal regions [36,37].”
BackgroundProteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Cdks, cyclins and CKIs: roles beyond cell cycle regulation
Lim, S., & Kaldis, P. (2013) · Development · doi:10.1242/dev.091744 · Cited by 1,487
“Collectively, it should be appreciated that the control of RNA Pol II-based transcription is analogous to the regulation of the cell cycle, whereby a series of Cdk/cyclin complexes, activities of which are restricted during each phase of the transcription cycle, is required to achieve the dynamic patterns of phosphory…”
BackgroundInfluentialGenomic correlates of clinical outcome in advanced prostate cancer
Abida, W., Cyrta, J., Heller, G., Prandi, D., Armenia, J., Coleman, I., Cieslik, M., Benelli, M., Robinson, D., Van Allen, E. M., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902651116 · Cited by 1,372
“We found strong co-occurrence of loss-of-function alterations in CDK12, a gene implicated in the control of genomic stability (20) whose inactivation in prostate cancer is associated with focal tandem duplications (21–23), with amplification of the cell-cycle genes CCND1 and CDK4, raising the possibility of vulnerabil…”
BackgroundLord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Robbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
The RNA polymerase II CTD coordinates transcription and RNA processing
Hsin, J.-P., & Manley, J. L. (2012) · Genes & Development · doi:10.1101/gad.200303.112 · Cited by 695
“Furthermore, depletion of CDK12 or the associated cyclin CycK in human cells reduced both total Ser2 levels and expression of select genes, including several DNA damage response genes (Blazek et al. 2011).”
BackgroundDing, L., Cao, J., Lin, W., Chen, H., Xiong, X., Ao, H., Yu, M., Lin, J., & Cui, Q. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061960 · Cited by 618
“CDK13 Cyclin K Transcript synthesis toward the middle and 3′ end of the emerging RNA Associated with DNA damage repair, genomic instability [47,81,82]”
BackgroundInactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieślik, M., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Ning, Y., Wang, L., Kunju, L. P., de Sarkar, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 598
Promoter-proximal pausing of RNA polymerase II: a nexus of gene regulation
Core, L., & Adelman, K. (2019) · Genes & Development · doi:10.1101/gad.325142.119 · Cited by 568
“Nonetheless, P-TEFb does not carry out the bulk of Pol II CTD Ser2-P; instead the kinases Cdk12 and Cdk13 contribute the majority of this modification (Bartkowiak et al. 2010; Blazek et al. 2011).”
BackgroundTung, N. M., Robson, M. E., Ventz, S., Santa-Maria, C. A., Nanda, R., Marcom, P. K., Shah, P. D., Ballinger, T. J., Yang, E. S., Vinayak, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.02151 · Cited by 508
The code and beyond: transcription regulation by the RNA polymerase II carboxy-terminal domain
Harlen, K. M., & Churchman, L. S. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.10 · Cited by 499
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
The RNA Polymerase II Carboxy-Terminal Domain (CTD) Code
Eick, D., & Geyer, M. (2013) · Chemical Reviews · doi:10.1021/cr400071f · Cited by 470
Study, T. I., Sifrim, A., the UK10K Consortium, Study, T. D. D. D., Hitz, M.-P., Wilsdon, A., Breckpot, J., Turki, S. H. A., Thienpont, B., McRae, J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3627 · Cited by 449
Genomic basis for RNA alterations in cancer
PCAWG Transcriptome Core Group, Calabrese, C., Davidson, N. R., Demircioğlu, D., Fonseca, N. A., He, Y., Kahles, A., Lehmann, K.-V., Liu, F., Shiraishi, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1970-0 · Cited by 393
“We find 91 samples that have an alteration involving its protein kinase domain, which has been implicated in DNA repair dysregulation 54 .”
BackgroundInhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
“CDK12 has also been associated with the regulation of a subset of genes required for the cellular response to DNA damage (Blazek et al., 2011).”
Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors
Zhang, T., Kwiatkowski, N., Olson, C. M., Dixon-Clarke, S. E., Abraham, B. J., Greifenberg, A. K., Ficarro, S. B., Elkins, J. M., Liang, Y., Hannett, N. M., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2166 · Cited by 374
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer
Quereda, V., Bayle, S., Vena, F., Frydman, S. M., Monastyrskyi, A., Roush, W. R., & Duckett, D. R. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.09.004 · Cited by 352
Targeting Cyclin-Dependent Kinases in Human Cancers: From Small Molecules to Peptide Inhibitors
Peyressatre, M., Prével, C., Pellerano, M., & Morris, M. (2015) · Cancers · doi:10.3390/cancers7010179 · Cited by 344
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease
Pellarin, I., Dall’Acqua, A., Favero, A., Segatto, I., Rossi, V., Crestan, N., Karimbayli, J., Belletti, B., & Baldassarre, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02080-z · Cited by 304
CDK12 regulates DNA repair genes by suppressing intronic polyadenylation
Dubbury, S. J., Boutz, P. L., & Sharp, P. A. (2018) · Nature · doi:10.1038/s41586-018-0758-y · Cited by 318
Dynamic phosphorylation patterns of RNA polymerase II CTD during transcription
Heidemann, M., Hintermair, C., Voß, K., & Eick, D. (2013) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2012.08.013 · Cited by 299
Transcription-Associated Cyclin-Dependent Kinases as Targets and Biomarkers for Cancer Therapy
Chou, J., Quigley, D. A., Robinson, T. M., Feng, F. Y., & Ashworth, A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0528 · Cited by 287
“Interestingly, CDK12 depletion does not affect transcription globally, but instead alters a select subset of genes involved in the DNA damage response (DDR) and DNA replication (61, 64).”
BackgroundJohnson, S. F., Cruz, C., Greifenberg, A. K., Dust, S., Stover, D. G., Chi, D., Primack, B., Cao, S., Bernhardy, A. J., Coulson, R., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.077 · Cited by 291
“Furthermore, short hairpin RNA (shRNA)mediated depletion of CDK12, or its cyclin K binding partner, from BRCA and CDK12 wild-type ovarian cancer or other transformed cell lines has been shown to suppress HR gene expression and sensitize cells to cisplatin-induced interstrand crosslinks and PARP inhibition (Bajrami et…”
BackgroundInfluentialKrajewska, M., Dries, R., Grassetti, A. V., Dust, S., Gao, Y., Huang, H., Sharma, B., Day, D. S., Kwiatkowski, N., Pomaville, M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09703-y · Cited by 281
The kinome 'at large' in cancer
Fleuren, E. D. G., Zhang, L., Wu, J., & Daly, R. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.18 · Cited by 264
Structural insights into the functional diversity of the CDK–cyclin family
Wood, D. J., & Endicott, J. A. (2018) · Open Biology · doi:10.1098/rsob.180112 · Cited by 260
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development–Review
Łukasik, P., Załuski, M., & Gutowska, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062935 · Cited by 245
“Depletion of the CDK12/CycK complex results in the downregulation of only a small subset of genes (predominantly long and complex ones) and does not affect global transcription rates [140].”
BackgroundFunctional genomics identifies therapeutic targets for MYC-driven cancer
Toyoshima, M., Howie, H. L., Imakura, M., Walsh, R. M., Annis, J. E., Chang, A. N., Frazier, J., Chau, B. N., Loboda, A., Linsley, P. S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121119109 · Cited by 242
“Finally, the enrichment in DNA-repair and -checkpoint genes (Dataset S1 for complete gene list) is consistent with the increased genomic instability and dramatic increase in the rate of DNA replication observed both in mammalian cells and in theXenopusmodel system caused byMYC overexpression (20, 31, 47).”
BackgroundInfluentialFunctional interrogation of DNA damage response variants with base editing screens
Cuella-Martin, R., Hayward, S. B., Fan, X., Chen, X., Huang, J.-W., Taglialatela, A., Leuzzi, G., Zhao, J., Rabadan, R., Lu, C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.041 · Cited by 241
“Finally, we explored the depletion phenotypes of sgRNAs targeting CDK12 (Figure S6A, Depletion, Table S6), a kinase that promotes the expression of DNA repair genes, including BRCA1 and ATR (Blazek et al., 2011).”
InfluentialFUS binds the CTD of RNA polymerase II and regulates its phosphorylation at Ser2
Schwartz, J. C., Ebmeier, C. C., Podell, E. R., Heimiller, J., Taatjes, D. J., & Cech, T. R. (2012) · Genes & Development · doi:10.1101/gad.204602.112 · Cited by 238
“Two kinases can phosphorylate the CTD at position Ser2: P-TEFb (Marshall and Price 1995; Ahn et al. 2004) and CDK12 (Bartkowiak et al. 2010; Blazek et al. 2011).”
BackgroundCandidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, D. R., Dougherty, B. A., Lai, Z., Fielding, A., Grinsted, L., Spencer, S., O’Connor, M. J., Ho, T. W., Robertson, J. D., Lanchbury, J. S., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0274-8 · Cited by 233
Prostate carcinogenesis: inflammatory storms
de Bono, J. S., Guo, C., Gurel, B., De Marzo, A. M., Sfanos, K. S., Mani, R. S., Gil, J., Drake, C. G., & Alimonti, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0267-9 · Cited by 227
The pol II CTD: new twists in the tail
Zaborowska, J., Egloff, S., & Murphy, S. (2016) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3285 · Cited by 226
PARP inhibitors: Clinical utility and possibilities of overcoming resistance
Bitler, B. G., Watson, Z. L., Wheeler, L. J., & Behbakht, K. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.10.003 · Cited by 217
“Mechanistically, knockdown of CDK12 leads to the concomitant downregulation of DNA repair proteins (such as BRCA1, FANC1, and ATR) thereby artificially establishing a “BRCAness” phenotype [51].”
BackgroundCyclins and Cell Cycle Control in Cancer and Disease
Casimiro, M. C., Crosariol, M., Loro, E., Li, Z., & Pestell, R. G. (2012) · Genes & Cancer · doi:10.1177/1947601913479022 · Cited by 216
“Irradiation of cells stimulated cyclin D1 binding to RAD51 and aided RAD51 recruitment to DNA damage foci in a process that was BRCA2 dependent.6 This finding was consistent with a prior finding that cyclin D1 bound BRCA1.”
BackgroundInfluentialDiscovery of a molecular glue promoting CDK12-DDB1 interaction to trigger cyclin K degradation
Lv, L., Chen, P., Cao, L., Li, Y., Zeng, Z., Cui, Y., Wu, Q., Li, J., Wang, J.-H., Dong, M.-Q., et al. (2020) · eLife · doi:10.7554/elife.59994 · Cited by 215
Joshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 199
“For example, depletion of ATR, which is also reduced by CDK12 knockdown (15), also disrupts HR (21).”
BackgroundResultInfluentialLiang, K., Gao, X., Gilmore, J. M., Florens, L., Washburn, M. P., Smith, E., & Shilatifard, A. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01426-14 · Cited by 192
“We confirmed that CDK12 regulates DNA damage response genes (11) and found that CDK13 is more specific for snRNA and snoRNA gene regulation.”
BackgroundInfluentialSerine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition
Czudnochowski, N., Bösken, C. A., & Geyer, M. (2012) · Nature Communications · doi:10.1038/ncomms1846 · Cited by 193
The structure and substrate specificity of human Cdk12/Cyclin K
Bösken, C. A., Farnung, L., Hintermair, C., Merzel Schachter, M., Vogel-Bachmayr, K., Blazek, D., Anand, K., Fisher, R. P., Eick, D., & Geyer, M. (2014) · Nature Communications · doi:10.1038/ncomms4505 · Cited by 191
Updating the RNA polymerase CTD code: adding gene-specific layers
Egloff, S., Dienstbier, M., & Murphy, S. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.03.007 · Cited by 177
Menghi, F., Barthel, F. P., Yadav, V., Tang, M., Ji, B., Tang, Z., Carter, G. W., Ruan, Y., Scully, R., Verhaak, R. G. W., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.06.008 · Cited by 174
“Defects in CDK12 are associated with the downregulation of critical regulators of genomic stability such as BRCA1, ATR, FANCI, and FANCD2 (Blazek et al., 2011; Joshi et al., 2014).”
BackgroundEWS/FLI confers tumor cell synthetic lethality to CDK12 inhibition in Ewing sarcoma
Iniguez, A. B., Stolte, B., Wang, E. J., Conway, A. S., Alexe, G., Dharia, N. V., Kwiatkowski, N., Zhang, T., Abraham, B. J., Mora, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.009 · Cited by 173
“The cyclin K-CDK12 complex has been shown to regulate the phosphorylation of the CTD of RNA Pol II (Blazek et al., 2011).”
InfluentialDavidson, L., Muniz, L., & West, S. (2014) · Genes & Development · doi:10.1101/gad.231274.113 · Cited by 170
“Whether Cdk12 performs a function analogous to Ctk1 in coordinating 39 end formation and transcription has not been tested.”
BackgroundInfluentialTargeting transcription cycles in cancer
Vervoort, S. J., Devlin, J. R., Kwiatkowski, N., Teng, M., Gray, N. S., & Johnstone, R. W. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00411-8 · Cited by 161
CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion
Tien, J. F., Mazloomian, A., Cheng, S.-W. G., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo-Gonzalez, G., Bashashati, A., Xu, J., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx187 · Cited by 163
“While several studies proposed that CDK12 specifically affects a small number of genes (5,76), another report suggested that CDK12 depletion causes a global downregulation of transcription (27).”
BackgroundResultInfluentialAflatoxin B1-induced epigenetic alterations: An overview
Dai, Y., Huang, K., Zhang, B., Zhu, L., & Xu, W. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.06.034 · Cited by 165
CDK13 cooperates with CDK12 to control global RNA polymerase II processivity
Fan, Z., Devlin, J. R., Hogg, S. J., Doyle, M. A., Harrison, P. F., Todorovski, I., Cluse, L. A., Knight, D. A., Sandow, J. J., Gregory, G., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz5041 · Cited by 164
Hintermair, C., Heidemann, M., Koch, F., Descostes, N., Gut, M., Gut, I., Fenouil, R., Ferrier, P., Flatley, A., Kremmer, E., et al. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.123 · Cited by 161
“New findings implicate CTD also in other nuclear processes such as chromatin modification (Govind et al , 2010; Spain and Govind, 2011) and transcription-coupled genome stability (Blazek et al , 2011).”
Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors
Chung, J. H., Dewal, N., Sokol, E., Mathew, P., Whitehead, R., Millis, S. Z., Frampton, G. M., Bratslavsky, G., Pal, S. K., Lee, R. J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00283 · Cited by 158
“6 (20) PARP Inhibitor Ovarian Swisher21 3B Mutation”
BackgroundCrosstalk between phosphorylation and O‐Glc NA cylation: friend or foe
van der Laarse, S. A. M., Leney, A. C., & Heck, A. J. R. (2018) · The FEBS Journal · doi:10.1111/febs.14491 · Cited by 158
Structural and functional analysis of the Cdk13/Cyclin K complex
Greifenberg, A. K., Hönig, D., Pilarova, K., Düster, R., Bartholomeeusen, K., Bösken, C. A., Anand, K., Blazek, D., & Geyer, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2015.12.025 · Cited by 157
“Five mammalian CDKs have been described to date as transcription regulating kinases together with their corresponding cyclin subunits: Cdk7/Cyclin H as components of the general transcription factor TFIIH (Gr€ unberg and Hahn, 2013), Cdk8/Cyclin C as components of the Mediator kinase module (Allen and Taatjes, 2015),…”
BackgroundMethodSelf-citationDiscovery and resistance mechanism of a selective CDK12 degrader
Jiang, B., Gao, Y., Che, J., Lu, W., Kaltheuner, I. H., Dries, R., Kalocsay, M., Berberich, M. J., Jiang, J., You, I., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00765-y · Cited by 150
Ekumi, K. M., Paculova, H., Lenasi, T., Pospichalova, V., Bösken, C. A., Rybarikova, J., Bryja, V., Geyer, M., Blazek, D., & Barboric, M. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv101 · Cited by 141
“In addition to the HR genes, depletion of Cdk12/CycK led to decreased expression of many other DDR genes (6).”
InfluentialChromatin-wide Profiling of DYRK1A Reveals a Role as a Gene-Specific RNA Polymerase II CTD Kinase
Vona, C. D., Bezdan, D., Islam, A. B. M. M. K., Salichs, E., López-Bigas, N., Ossowski, S., & de la Luna, S. (2015) · Molecular Cell · doi:10.1016/j.molcel.2014.12.026 · Cited by 158
“, local activation of other CTD kinases or inhibition of CTD phosphatases) or that may even be independent of the CTD, our data are consistent with DYRK1A being a gene-specific CTD kinase, as in the case of CDK12 or ERK2 (Blazek et al., 2011; Tee et al., 2014).”
ResultInfluentialThe RNA Polymerase II CTD: The Increasing Complexity of a Low-Complexity Protein Domain
Jerónimo, C., Collin, P., & Robert, F. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.02.006 · Cited by 151
CDK12: an emerging therapeutic target for cancer
Lui, G. Y. L., Grandori, C., & Kemp, C. J. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205356 · Cited by 131
CDK1 in Breast Cancer: Implications for Theranostic Potential
Izadi, S., Nikkhoo, A., Hojjat‐Farsangi, M., Namdar, A., Azizi, G., Mohammadi, H., Yousefi, M., & Jadidi‐Niaragh, F. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200203125712 · Cited by 150
CDK9 inhibitors define elongation checkpoints at both ends of RNA polymerase II–transcribed genes
Laitem, C., Zaborowska, J., Isa, N. F., Kufs, J., Dienstbier, M., & Murphy, S. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3000 · Cited by 133
Popova, T., Manié, E., Boeva, V., Battistella, A., Goundiam, O., Smith, N. K., Mueller, C. R., Raynal, V., Mariani, O., Sastre-Garau, X., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2128 · Cited by 130
“Effect of CDK12 knockdown in cellular models has been consistently associated with HR deficiency (HRD) (3,5,7,8).”
BackgroundInfluentialCheng, S.-W. G., Kuzyk, M. A., Moradian, A., Ichu, T.-A., Chang, V. C.-D., Tien, J. F., Vollett, S. E., Griffith, M., Marra, M. A., & Morin, G. B. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.06267-11 · Cited by 124
Targeting cell cycle regulators in hematologic malignancies
Aleem, E., & Arceci, R. J. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00016 · Cited by 120
“CDK12 and CDK13 in complex with cyclin K control RNA pol II transcription (Bartkowiak et al., 2010; Blazek et al., 2011; Cheng et al., 2012), and CDK12/cyclin K controls DNA damage response (Blazek et al., 2011).”
BackgroundCyclin K goes with Cdk12 and Cdk13
Kohoutek, J., & Blažek, D. (2012) · Cell Division · doi:10.1186/1747-1028-7-12 · Cited by 143
“It associates with Cdk12 and Cdk13 in two separate complexes, but not with its previously identified partner, Cdk9 [5].”
BackgroundSelf-citationA Non-catalytic Function of SETD1A Regulates Cyclin K and the DNA Damage Response
Hoshii, T., Cifani, P., Feng, Z., Huang, C., Koche, R. P., Chen, C.-W. D., Delaney, C. D., Lowe, S. W., Kentsis, A., & Armstrong, S. A. (2018) · Cell · doi:10.1016/j.cell.2018.01.032 · Cited by 132
“This is in keeping with the recent demonstration that the cyclin K/CDK12 complex is a regulator of DNA damage response genes (Blazek et al., 2011; Greifenberg et al., 2016).”
BackgroundResultStrategies for designing proteolysis targeting chimaeras (PROTACs)
He, S., Dong, G., Cheng, J., Wu, Y., & Sheng, C. (2022) · Medicinal Research Reviews · doi:10.1002/med.21877 · Cited by 108
“CDK12, an important member of CDKs, plays a key role in regulating the transcription of genes that respond to DNA damage.(186) However, the understanding of biological function of CDK12 is hampered by its homologous”
BackgroundChoi, H., Jin, S., Cho, H., Won, H., An, H. W., Jeong, G., Park, Y., Kim, H., Park, M. K., Son, T., et al. (2019) · EMBO reports · doi:10.15252/embr.201948058 · Cited by 117
Albert, T. K., Rigault, C., Eickhoff, J., Baumgart, K., Antrecht, C., Klebl, B., Mittler, G., & Meisterernst, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12408 · Cited by 119
“For example, the pan-specific flavopiridol could target additional CTD-Ser2 kinases such as CDK12 and/or CDK13 (Bartkowiak et al., 2010; Blazek et al., 2011).”
BackgroundNguyen, B., Mota, J. M., Nandakumar, S., Stopsack, K. H., Weg, E. S., Rathkopf, D. E., Morris, M. J., Scher, H. I., Kantoff, P. W., Gopalan, A., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.024 · Cited by 134
RNA Polymerase II Transcription Elongation Control
Guo, J., & Price, D. H. (2013) · Chemical Reviews · doi:10.1021/cr400105n · Cited by 136
Chen, R., Bélanger, S., Frederick, M. A., Li, B., Johnston, R. J., Xiao, N., Liu, Y.-C., Sharma, S., Peters, B., Rao, A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.08.002 · Cited by 117
Gu, B., Eick, D., & Bensaude, O. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks1327 · Cited by 146
“However, the effects of either knocking-out or inhibition of Ser2 kinase might be hard to interpret: First, several kinases such as CDK9, Ctk1, CDK12 and CDK13 preferentially phosphorylate Ser2 in vitro (23,24); therefore, blocking CDK9 or deleting Ctk1 might not totally inhibit Ser2 phosphorylation”
BackgroundCDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes
Chirackal Manavalan, A. P., Pilarova, K., Kluge, M., Bartholomeeusen, K., Rajecky, M., Oppelt, J., Khirsariya, P., Paruch, K., Krejci, L., Friedel, C. C., et al. (2019) · EMBO reports · doi:10.15252/embr.201847592 · Cited by 110
“As long-term CDK12 depletion causes down-regulation of DNA repair genes resulting in endogenous DNA damage [11,23], we asked whether the observed G1/S delay upon CDK12 inhibition was ▸ due to secondary activation of DNA damage cell cycle checkpoints [50].”
InfluentialSelf-citationClinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer
Reimers, M. A., Yip, S., Zhang, L., Cieslik, M. P., Dhawan, M., Montgomery, B., Wyatt, A. W., Chi, K. N., Small, E. J., Chinnaiyan, A. M., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.09.036 · Cited by 125
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Keung, M. Y., Wu, Y., Badar, F., & Vadgama, J. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040940 · Cited by 120
“CDK12 plays an essential role in DNA repair and the maintenance of genomic stability [43,44].”
BackgroundPerspective of Cyclin-dependent kinase 9 (CDK9) as a Drug Target
Kryštof, V., Baumli, S., & Fürst, R. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672750 · Cited by 121
“Facilitated by their localization close to chromatin, CDKs 12 and 13 play additional roles in maintenance of genome integrity [2,20].”
BackgroundNatrajan, R., Wilkerson, P. M., Marchiò, C., Piscuoglio, S., Ng, C. K., Wai, P., Lambros, M. B., Samartzis, E. P., Dedes, K. J., Frankum, J., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4325 · Cited by 109
“CDK12-deficient cells display spontaneous DNA damage and are sensitive to a variety of DNA damage agents[48].”
RNA Processing and Genome Stability: Cause and Consequence
Wickramasinghe, V. O., & Venkitaraman, A. R. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.001 · Cited by 118
“For instance, DDR gene expression is regulated during transcription elongation (Blazek et al., 2011), mRNA splicing (Paronetto et al., 2011; Savage et al., 2014), mRNA export (Wickramasinghe et al., 2013), miRNA regulation (Moskwa et al., 2011), or translation (Powley et al., 2009).”
Bowman, E. A., & Kelly, W. G. (2014) · Nucleus · doi:10.4161/nucl.29347 · Cited by 107
Wang, C., Wang, H., Lieftink, C., du Chatinier, A., Gao, D., Jin, G., Jin, H., Beijersbergen, R. L., Qin, W., & Bernards, R. (2020) · Gut · doi:10.1136/gutjnl-2019-318506 · Cited by 107
SIRT2 directs the replication stress response through CDK9 deacetylation
Zhang, H., Park, S., Pantazides, B. G., Karpiuk, O., Warren, M. D., Hardy, C. W., Duong, D. M., Park, S., Kim, H. S., Vassilopoulos, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1301463110 · Cited by 117
“The role for CDK9 in the RSR is independent of cyclin T (29), and we and others have shown that cyclin K also functions to maintain genome integrity (29, 35); however, recent evidence suggests that cyclin K functions primarily with CDK12 (35–37).”
BackgroundHuman CDK12 and CDK13, multi-tasking CTD kinases for the new millenium
Greenleaf, A. L. (2019) · Transcription · doi:10.1080/21541264.2018.1535211 · Cited by 102
“Peterlin and co-workers [13] found that knockdown of human CDK12 led to altered CTD phosphorylation in cells, and they also showed that knockdown of Cyclin K gave a similar result.”
BackgroundMethodResultInfluentialTherapeutic targeting of transcriptional cyclin-dependent kinases
Galbraith, M. D., Bender, H., & Espinosa, J. M. (2018) · Transcription · doi:10.1080/21541264.2018.1539615 · Cited by 111
“In contrast, there is evidence that CDK12, rather than CDK9, is the major CTD S5 kinase during transcription elongation in vivo [118,120], and its recruitment to transcription units is mediated by the PAF1 complex [121].”
BackgroundInfluentialCdk12 is essential for embryonic development and the maintenance of genomic stability
Juan, H.-C., Lin, Y., Chen, H.-R., & Fann, M.-J. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2015.157 · Cited by 104
“exhibit similar embryonic lethality phenotype to that of Cdk12 −/− mice.(14) Exploring cyclin K expression and its”
BackgroundDissecting the Pol II transcription cycle and derailing cancer with CDK inhibitors
Parua, P. K., & Fisher, R. P. (2020) · Nature Chemical Biology · doi:10.1038/s41589-020-0563-4 · Cited by 119
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 105
“The most altered genes are those with large number of exons, which includes BRCA1, ATR, FANCI, and FANCD2 (11, 14).”
BackgroundTellier, M., Zaborowska, J., Caizzi, L., Mohammad, E., Velychko, T., Schwalb, B., Vicens, I. F., Blears, D., Nojima, T., Cramer, P., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa514 · Cited by 122
“Several studies using RNAi-mediated knockdown of CDK12 have highlighted roles for this kinase in CTD phosphorylation and expression of DDR genes (3,4,17).”
InfluentialCharacterizing CDK12-Mutated Prostate Cancers
Rescigno, P., Gürel, B., Pereira, R., Crespo, M., Rekowski, J., Rediti, M., Barrero, M., Mateo, J., Bianchini, D., Messina, C. G. M., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2371 · Cited by 116
“heterodimeric complex with Cyclin K (CycK) implicated in DNA repair (DDR), splicing, and differentiation [1-6].”
BackgroundCDK9 keeps RNA polymerase II on track
Egloff, S. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03878-8 · Cited by 113
PARP Inhibitors and Prostate Cancer: To Infinity and BeyondBRCA
Risdon, E. N., Chau, C. H., Price, D. K., Sartor, O. A., & Figg, W. D. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0697 · Cited by 117
“Through this mechanism, the transcription of several DDR repair genes, including BRCA1 and ATR, is CDK12 dependent [91, 92].”
BackgroundImmune Checkpoint Inhibitors in Prostate Cancer
Venkatachalam, S., McFarland, T. R., Agarwal, N., & Swami, U. (2021) · Cancers · doi:10.3390/cancers13092187 · Cited by 106
“In an analysis of 360 mCRPC patients, the loss of cyclin-dependent kinase (CDK12) that controls DNA damage response) was seen to be associated with focal tandem duplications, increased gene fusion, neoantigen burden, and T cell infiltrations, suggesting that this subset of prostate cancer patients might benefit from i…”
Degradation of CCNK/CDK12 is a druggable vulnerability of colorectal cancer
Dieter, S. M., Siegl, C., Codó, P. L., Huerta, M., Ostermann-Parucha, A. L., Schulz, E., Zowada, M. K., Martin, S., Laaber, K., Nowrouzi, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109394 · Cited by 95
How Selective Are Pharmacological Inhibitors of Cell-Cycle-Regulating Cyclin-Dependent Kinases?
Jorda, R., Hendrychová, D., Voller, J., Řezníčková, E., Gucký, T., & Kryštof, V. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00049 · Cited by 97
Wang, Z., Wu, Z., Raitskin, O., Sun, Q., & Dean, C. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1406635111 · Cited by 96
“Recent studies demonstrating a second metazoan CTD Ser(2) kinase (54, 55) suggest that the paradigm of CTD Ser(2) kinase pairs might be retained throughout higher eukaryotes.”
BackgroundRieswijk, L., Claessen, S. M. H., Bekers, O., van Herwijnen, M. H. M., Theunissen, D. H. J., Jennen, D. G. J., de Kok, T. M. C. M., Kleinjans, J. C. S., & van Breda, S. G. (2016) · Toxicology · doi:10.1016/j.tox.2016.05.002 · Cited by 98
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors
Kalra, S., Joshi, G., Munshi, A., & Kumar, R. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.071 · Cited by 98
U1 snRNP increases RNA Pol II elongation rate to enable synthesis of long genes
Mimoso, C. A., & Adelman, K. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.002 · Cited by 111
Metadata
- Authors
- Blazek, D., Kohoutek, J., Bartholomeeusen, K., Johansen, E., Hulinkova, P., Luo, Z., Cimermancic, P., Ule, J., & Peterlin, B. M.
- Affiliations
- University of California, San Francisco (US)
- MRC Laboratory of Molecular Biology (GB)
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2011-10-15
- Volume
- 25
- Issue
- 20
- Pages
- 2158-2172
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- PMC
- PMC3205586
- OpenAlex
- W2123814549
- Cited by
- 522
- References
- 57
- Citations by year
- 2026: 40 · 2025: 36 · 2024: 52 · 2023: 40 · 2022: 35 · 2021: 40 · 2020: 52 · 2019: 45 · 2018: 33 · 2017: 24 · 2016: 29 · 2015: 25 · 2014: 23 · 2013: 24 · 2012: 24
- Type
- posted content
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Genes & Development (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Funders
- Wellcome Trust (089701)
- Grantová Agentura České Republiky
- National Institutes of Health (GM082250)
- National Institute of General Medical Sciences (P50GM082250, IP50 GM082250)
- National Institute of Allergy and Infectious Diseases (R01AI49104, R01AI049104)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- cyclin K, CDK12, CDK13, RNA polymerase II Ser2 phosphorylation, transcriptional regulation, DNA damage response genes, genome stability, BRCA1, ATR, FANCI, FANCD2, spontaneous DNA damage, embryonic lethality
- MeSH terms
- Animals, DNA Damage, HeLa Cells, Humans, Phosphorylation, CDC2 Protein Kinase, Cyclins, Mice, Knockout, Gene Expression Regulation, Developmental, Cyclin-Dependent Kinases, Genomic Instability, Cyclin-Dependent Kinase 9, Mice, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.